Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis-Reference-Cited by-同舟云学术

Long-term outcomes of neoadjuvant immunotherapy plus chemotherapy in patients with early-stage triple-negative breast cancer: an extracted individual patient data and trial-level meta-analysis

Published:2023-11-27 Issue:2 Volume:130 Page:242-250
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Cunha Mateus Trinconi^ORCID,Gouveia Mariana Carvalho,Neto Felippe Lazar,Testa Laura,Hoff Paulo Marcelo,de Azambuja Evandro,Bonadio Renata Colombo

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://www.nature.com/articles/s41416-023-02501-w.pdf

Reference35 articles.

1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13:4429–34.

2. Liedtke C, Rody A, Gluz O, Baumann K, Beyer D, Kohls E-B, et al. The prognostic impact of age in different molecular subtypes of breast cancer. Breast Cancer Res. Treat. 2015;152:667–73.

3. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.

4. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164–72.

5. Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet. 2020;396:1090–100.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Outcomes after Postoperative Radiotherapy in Triple-Negative Breast Cancer: Multi-Institutional Retrospective Study (KROG 17-05);Journal of Personalized Medicine;2024-09-04

2. Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer;ESMO Real World Data and Digital Oncology;2024-09

3. Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer;npj Breast Cancer;2024-08-14

4. Medical Statistics in Drug Development and Regulatory Approval;Advances in Bioinformatics and Biomedical Engineering;2024-07-18

5. Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial;Breast Cancer: Targets and Therapy;2024-04